Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 25 April 2008:
Vol. 320. no. 5875, pp. 520 - 523
DOI: 10.1126/science.1156609
Prev | Table of Contents | Next

Reports

Efficient Inhibition of the Alzheimer's Disease β-Secretase by Membrane Targeting

Lawrence Rajendran,1 Anja Schneider,2 Georg Schlechtingen,3,4 Sebastian Weidlich,4 Jonas Ries,5 Tobias Braxmeier,3,4 Petra Schwille,5 Jörg B. Schulz,6 Cornelia Schroeder,4 Mikael Simons,2 Gary Jennings,3 Hans-Joachim Knölker,3,4 Kai Simons1*

β-Secretase plays a critical role in β-amyloid formation and thus provides a therapeutic target for Alzheimer's disease. Inhibitor design has usually focused on active-site binding, neglecting the subcellular localization of active enzyme. We have addressed this issue by synthesizing a membrane-anchored version of a β-secretase transition-state inhibitor by linking it to a sterol moiety. Thus, we targeted the inhibitor to active β-secretase found in endosomes and also reduced the dimensionality of the inhibitor, increasing its local membrane concentration. This inhibitor reduced enzyme activity much more efficiently than did the free inhibitor in cultured cells and in vivo. In addition to effectively targeting β-secretase, this strategy could also be used in designing potent drugs against other membrane protein targets.

1 Max Planck Institute of Molecular Cell Biology and Genetics, Pfotenhauerstr. 108, 01307 Dresden, Germany.
2 Max Planck Institute for Experimental Medicine, 37075 Göttingen, Germany.
3 JADO Technologies GmbH, Tatzberg 47-51, 01307 Dresden, Germany.
4 Department of Chemistry, Technical University of Dresden, Bergstr. 66, 01069 Dresden, Germany.
5 Biotec, Biotechnologisches Zentrum, Tatzberg 47/49, 01307 Dresden, Germany.
6 Center of Neurological Medicine, Waldweg 33, 37073 Göttingen, Germany.

* To whom correspondence should be addressed. E-mail: simons{at}mpi-cbg.de

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Targeted Inhibition of Amyloid-Beta.
(2008)
Journal Watch Neurology 2008, 3
   Full Text »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)